Milrinone Tillomed

Milrinone, the active ingredient in Milrinone Tillomed, is a phosphodiesterase‑3 inhibitor presented as an intravenous solution for intravenous use. It is employed to increase cardiac output in patients experiencing acute decompensated heart failure or cardiogenic shock, conditions where the heart’s pumping ability is severely compromised. GNH USA supplies Milrinone Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Milrinone acts as an inotropic and vasodilator agent in acute cardiac conditions. - Acute decompensated heart failure: improves contractility and reduces systemic vascular resistance, helping restore adequate circulation. - Cardiogenic shock: provides rapid inotropic support to maintain organ perfusion during severe circulatory collapse. - Post‑cardiac surgery low‑output syndrome: assists in stabilising hemodynamics when the heart fails to generate sufficient output after operative procedures.

Milrinone may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially with rapid infusion. - Arrhythmias: premature ventricular contractions or tachycardia. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Flushing: transient warmth and redness of the skin. - Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects: - Severe ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Extreme hypotension: profound drop in blood pressure requiring intervention. - Anaphylactic or severe allergic reactions: rash, bronchospasm, or shock. - Thrombosis: formation of clots in veins or arteries.

Milrinone requires careful monitoring and specific safety measures before and during therapy. - Blood pressure monitoring: watch for hypotension, especially during dose titration. - Cardiac rhythm surveillance: continuous ECG to detect arrhythmias. - Renal function assessment: dose may need adjustment in renal impairment. - Severe aortic stenosis: avoid use due to risk of excessive afterload reduction. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase milrinone plasma levels. - Concurrent use with other phosphodiesterase inhibitors: risk of profound vasodilation. - Nitrates or other potent vasodilators: can cause severe hypotension. - High‑dose β‑agonists: may precipitate arrhythmias. - Digoxin: combined use may heighten arrhythmic risk.

Moderate Interactions (Monitor Closely): - Diuretics: may amplify electrolyte shifts and hypotension. - ACE inhibitors or ARBs: additive blood‑pressure lowering effect. - Anticoagulants: monitor for bleeding if thrombocytopenia occurs. - Beta‑blockers: may blunt desired inotropic response. - Other inotropes: careful titration required to avoid over‑stimulation.